Tag: Viz.AI
Viz.ai announces study findings demonstrating real-world impact of AI-driven stroke technology
Viz.ai has announced the presentation of three new abstracts that demonstrate the real-world impact of the Viz neuro suite at this week’s Society of...
Viz.ai collaborates with Johns Hopkins to expedite patient enrolment in brain...
Viz.ai has announced a collaboration with BIOS Clinical Trials Coordinating Center (BIOS CTTC) at Johns Hopkins University (Baltimore, USA) to expedite patient enrolment for...
Real-world study demonstrates “highly clinically important” time saving with Viz platform
Viz.ai and TeleSpecialists have announced new data presented at the 2023 International Stroke Conference (ISC; 8–10 February, Dallas, USA) from the VALIDATE study, which...
Viz.ai partners with Cercare to support neurovascular clinical decision-making
Viz.ai has announced a partnership with Cercare Medical that will incorporate the latter’s Cercare Perfusion—a fully-automated, simple-to-use, patient-specific perfusion software—into the Viz artificial intelligence...
Viz.ai and Vastrax join forces to accelerate neurovascular clinical trial enrolment
Viz.ai has announced a strategic partnership with full-service, vascular clinical research organisation (CRO) Vastrax. Together, the two companies intend to accelerate clinical trial enrolment for...
New study finds 85% of aneurysms identified by Viz ANEURYSM had...
Viz.ai has shared highlights from new data set to be presented at next week’s Society of Vascular and Interventional Neuroradiology (SVIN) annual meeting (16–19...
Viz.ai receives US FDA 510(k) clearance for Viz SDH, announces Hyperfine...
Viz.ai today announced it has received US Food and Drug Administration (FDA) 510(k) clearance for Viz Subdural (SDH). The Viz SDH algorithm uses artificial...
Viz.ai raises US$100 million in Series D funding to expand AI...
Viz.ai has raised a US$100 million funding round at a US$1.2 billion valuation, as per a company press release. The Series D round, which...
Viz.ai receives FDA 510(k) clearance for cerebral aneurysm detection algorithm
Viz.ai has received US Food and Drug Administration (FDA) 510(k) clearance for Viz ANEURYSM—a new algorithm that uses artificial intelligence (AI) to detect suspected...
New data presented at ISC 2022 further validate real-world impact of...
Data from several new studies presented at the recent International Stroke Conference (ISC 2022; 9–11 February, New Orleans, USA) further validate the “best-in-class” sensitivity and...
Time savings, cost reductions and improved patient outcomes all key benefits...
Artificial intelligence (AI) and the role it can play in improving acute ischaemic stroke care protocols took centre stage at the Barts Research and...
Viz.ai debuts AI-powered cerebral aneurysm detection technology at SVIN 2021
At this year’s Society of Vascular and Interventional Neurology annual meeting (SVIN 2021; 17–20 November, Phoenix, USA and virtual), Viz.ai introduced Viz ANX, a...
Viz.ai receives CE mark to bring AI-powered stroke care software to...
Viz.ai has been awarded a CE mark for its artificial intelligence (AI)-powered stroke care software, affirming its conformity with European health, safety and environmental...
Medtronic, Viz.ai partner to bring “lifesaving” AI platform for stroke to...
Medtronic and Viz.ai have announced they are extending their successful US partnership to distribute Viz.ai’s "lifesaving" artificial intelligence (AI) software platform for stroke to...
Viz.ai adds new capabilities to its AI stroke platform
Viz.ai has launched the next generation of its synchronized care platform for stroke. Viz.ai incorporates cutting edge artificial intelligence with HIPAA-compliant communication to allow...
Viz.ai launches a range of new AI features
Viz.ai has announced a number of new features at the Society of Vascular and Interventional Neurology (SVIN) annual meeting in Atlanta, USA (20–23 November,...
Although “unperfected”, AI has the potential to accelerate and synchronise stroke...
A recently published systematic review reveals that artificial intelligence (AI) is rapidly being used by major medical centres to identify large vessel occlusions (LVO)...
Viz.ai and NICO announce collaboration to speed patient recruitment in the...
Viz.ai and NICO have announced a collaboration to incorporate a new innovative clinical trial recruitment software from Viz.ai into the seminal ENRICH study which...
New results demonstrate ability to automatically detect suspected large-vessel occlusion stroke...
Viz.ai has further advanced the field of stroke imaging and workflow by developing a novel method for the detection of signs of large vessel...
Viz.ai designated as American Heart Association/American Stroke Association Get With the...
Viz.ai, an applied artificial intelligence company, has been designated as a compatible vendor for the American Heart Association/American Stroke Association Get With The Guidelines...
FDA permits marketing of software that may alert doctors of stroke...
The US Food and Drug Administration have permitted the marketing of the Viz.AI Contact application, a type of clinical decision support software designed to...
